Nurix Therapeutics, Inc. (NRIX)
| Market Cap | 1.68B +90.2% |
| Revenue (ttm) | 71.78M +27.2% |
| Net Income | -295.28M |
| EPS | -3.17 |
| Shares Out | 103.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 663,142 |
| Open | 16.88 |
| Previous Close | 16.88 |
| Day's Range | 15.86 - 16.88 |
| 52-Week Range | 8.20 - 22.50 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 30.50 (+87.35%) |
| Earnings Date | Apr 8, 2026 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical tr... [Read more]
Financial Performance
In fiscal year 2025, Nurix Therapeutics's revenue was $83.98 million, an increase of 53.95% compared to the previous year's $54.55 million. Losses were -$264.46 million, 36.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 87.35% from the latest price.
News
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther...
Nurix Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Lead BTK degrader is advancing to phase III for CLL, showing strong efficacy and safety, with a new confirmatory trial against pirtobrutinib. Autoimmune and early-stage programs are progressing, and the company is well-funded with $650M in cash.
Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo
Wells Fargo lowered the firm’s price target on Nurix Therapeutics (NRIX) to $28 from $29 and keeps an Overweight rating on the shares. While management continues to execute on bexdeg’s
Nurix Therapeutics price target lowered to $34 from $35 at Stifel
Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $35 and keeps a Buy rating on the shares after the company reported a GAAP net loss
Nurix Therapeutics reports Q1 EPS (79c), consensus (76c)
Reports Q1 revenue $6.3M, consensus $14.24M. Cash, cash equivalents and marketable securities were $540.7M as of February 28, 2026, compared to $592.9M as of November 30, 2025. “Nurix entered 2026
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL)
Nurix Therapeutics to Participate in Upcoming Investor Conference
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Nurix Therapeutics Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium
Degrader therapies in immunology offer advantages over inhibitors by eliminating entire protein functions, enabling targeting of challenging proteins like STAT6. Key programs, including STAT6 (with Sanofi), BTK, and IRAK4 (with Gilead), are advancing, with major clinical milestones expected this year.
Nurix Therapeutics price target raised to $35 from $33 at Stifel
Stifel raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $33 and keeps a Buy rating on the shares following the Q4 report. The firm continues to
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
Wells Fargo analyst Derek Archila lowered the firm’s price target on Nurix Therapeutics (NRIX) to $29 from $30 and keeps an Overweight rating on the shares. While there are not
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler
Piper Sandler raised the firm’s price target on Nurix Therapeutics (NRIX) to $35 from $32 and keeps an Overweight rating on the shares following quarterly results and pipeline update. The
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $31 and keeps a Buy rating on the shares. The firm updated the company’s model post
Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)
Reports Q4 revenue $13.6M, consensus $13.41M. “The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak registrational program for bexobrutideg and strengthened our ...
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile i...
Nurix Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Bexobrutideg achieved strong clinical results in CLL, with an 83% response rate and 22.1 months PFS, supporting pivotal and head-to-head phase III trials. The pipeline expands into autoimmune and CNS diseases, with robust financials and industry enthusiasm for the degrader class.
Nurix Therapeutics highlights key objectives, milestones
Nurix Therapeutics (NRIX) highlighted the Company’s achievements in 2025 and outlined key objectives and anticipated milestones for 2026. Key highlights include: Execute a program for BTK degrader, be...
Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases
Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymph...
Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Nurix Therapeutics (NRIX) to Overweight from Equal Weight with a price target of $36, up from $15. The firm sees a higher probability of success for bexobrutideg
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of t...
Nurix Therapeutics price target raised to $30 from $24 at Mizuho
Mizuho raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $24 and keeps an Outperform rating on the shares. The key opinion leader with which the firm
Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nurix Therapeutics (NRIX) to $31 from $28 and keeps a Buy rating on the shares. The firm says the
Nurix Therapeutics price target raised to $30 from $27 at BTIG
BTIG raised the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $27 and keeps a Buy rating on the shares. The company hosted a webcast to discuss updated
Nurix Therapeutics Transcript: Study Update
Bexobrutideg demonstrated an 83% response rate and 22-month median PFS in heavily pretreated CLL, including those with CNS involvement and high-risk mutations, with a favorable safety profile. Waldenstrom's patients showed 75–83% response rates. The pivotal DAYBreak program is underway, with combination and front-line studies planned.
Nurix Therapeutics presents data from Phase 1 trial of bexobrutideg
Nurix Therapeutics (NRIX) presented new clinical data from patients with relapsed or refractory Waldenstrom macroglobulinemia treated in the Phase 1 clinical trial of its Bruton’s tyrosine kinase degr...